Physician profile
Christopher Rogers
NPI 1013937036
$32,396.29
in general payments reported to CMS, 2019-2025
35 companies · $3,336 in 2025
The $3,336 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,251 · 2020: $562 · 2021: $1,557 · 2022: $5,837 · 2023: $1,912 · 2024: $17K · 2025: $3,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $11K · Food and Beverage: $6,260 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $10,930.77 |
| Food and Beverage | $6,259.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $17,781.47 | 2021-2025 | Corevalve Evolut R, Apollotm, Cobalt Dr Mri Surescan |
| Boston Scientific Corporation | $6,324.31 | 2019-2025 | Watchman Access System, Watchman Flx, Opticross |
| Abbott Laboratories | $2,485.41 | 2019-2025 | Jot Dx, Aveir, Cardiomems |
| Edwards Lifesciences Corporation | $1,297.03 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Pascal |
| Medtronic Vascular, INC. | $739.53 | 2019-2020 | |
| Shockwave Medical, INC | $630.20 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $487.71 | 2019-2025 | |
| Cardiva Medical, INC. | $412.91 | 2023-2025 | Optowire, Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Pfizer INC. | $354.85 | 2019-2025 | |
| Cardiovascular Systems INC. | $317.19 | 2020-2022 | |
| Abiomed | $205.88 | 2019-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $171.70 | 2022-2024 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $148.32 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $130.80 | 2020-2024 | Opsumit |
| Daiichi Sankyo INC. | $96.09 | 2021-2025 | Injectafer |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $88.56 | 2019-2022 | |
| Amgen INC. | $85.77 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $72.90 | 2020-2023 | |
| Teleflex LLC | $70.52 | 2022-2024 | Langston |
| Amarin Pharma, INC. | $62.92 | 2019-2021 | |
| Lantheus Medical Imaging, INC. | $53.60 | 2023 | Definity |
| Regeneron Healthcare Solutions, INC. | $48.64 | 2023 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $45.52 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $40.01 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.33 | 2019-2022 | |
| Chiesi USA, INC. | $35.61 | 2023 | Cleviprex, Kengreal |
| Kiniksa Pharmaceuticals, Ltd. | $33.86 | 2022-2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.01 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $18.50 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $18.26 | 2021 | |
| Scpharmaceuticals INC. | $15.95 | 2024 | |
| Cordis US Corp. | $15.65 | 2025 | Mynxgrip |
| Livanova USA, INC. | $14.39 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.11 | 2022 | |
| Cardinal Health 200 LLC | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.